Journal of Clinical Oncology, Vol 15, 2231-2237, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. Berlin-Frankfurt-Munster Study Group

B Beyermann, HP Adams and G Henze
Department of Pediatric Oncology/Hematology, Children's Hospital, Virchow Medical Center, Humboldt University, Berlin, Germany.

PURPOSE: The translocation t(9;22)(q34;q11), known as Philadelphia chromosome (Ph1) or its molecular equivalent the expression of BCR-ABL- mRNA, is one of the most striking and well-characterized cytogenetic abnormalities in leukemia. Although investigated for more than 30 years, it remains unclear whether the Ph1 is an independent risk factor for outcome of leukemia or not. METHODS: A matched-pair analysis was performed within a homogeneous group of patients, which consisted of children who presented with a first relapse of acute lymphoblastic leukemia (ALL) who were treated according to ALL relapse trials (ALL- REZ BFM) protocols. A total of 307 patients were eligible for this analysis: 30 positive and 277 negative for Ph1. Positive patients were matched exactly for time point of relapse (on [during] or off [after cessation of] front-line therapy), site, and immunophenotype, and as close as possible for duration of first remission, peripheral blast- cell count, WBC count, and year of relapse diagnosis. RESULTS: The probability of event-free survival is 0.46 at 5 years for negative and 0.11 for positive patients, respectively (P = .0006). Multivariate analysis showed risk ratios of 4.229 for relapse on therapy, 3.561 for Ph1 and/or expression of BCR-ABL- mRNA, 1.691 for high peripheral blast- cell count, and 0.232 for bone marrow transplantation. CONCLUSION: It was shown that the Ph1 is indeed an independent risk factor in childhood relapsed ALL. There are striking similarities between these patients and children at initial diagnosis, as well as adult patients. Therefore, it is highly suggestive that the Ph1 is also an independent risk factor under all of these circumstances.

This article has been cited by other articles:

				S. Moqattash and J. D. Lutton Leukemia Cells and the Cytokine Network: Therapeutic Prospects Experimental Biology and Medicine, February 1, 2004; 229(2): 121 - 137. [Abstract] [Full Text] [PDF]

				A. Borgmann, A. von Stackelberg, R. Hartmann, W. Ebell, T. Klingebiel, C. Peters, and G. Henze Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis Blood, May 15, 2003; 101(10): 3835 - 3839. [Abstract] [Full Text] [PDF]

				K. Seeger, A. V. Stackelberg, T. Taube, D. Buchwald, G. Korner, M. Suttorp, W. Dorffel, W. Tausch, and G. Henze Relapse of TEL-AML1-Positive Acute Lymphoblastic Leukemia in Childhood: A Matched-Pair Analysis J. Clin. Oncol., July 1, 2001; 19(13): 3188 - 3193. [Abstract] [Full Text] [PDF]

				C. A. Felix, B. J. Lange, and J. M. Chessells Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000 Hematology, January 1, 2000; 2000(1): 285 - 302. [Abstract] [Full Text] [PDF]

				K. Seeger, H.-P. Adams, D. Buchwald, B. Beyermann, B. Kremens, C. Niemeyer, J. Ritter, D. Schwabe, D. Harms, M. Schrappe, et al. TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia Blood, March 1, 1998; 91(5): 1716 - 1722. [Abstract] [Full Text] [PDF]